Related Experiment Video

Updated: Mar 6, 2026

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials
06:18

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials

Published on: March 3, 2023

1.9K

Population pharmacokinetics of vancomycin in Chinese pediatric patients


Taotao Liu, Chen Deng, Daohai Cheng

    International Journal of Clinical Pharmacology and Therapeutics
    |March 4, 2017
    PubMed

    Insights

    This study developed a population pharmacokinetic model for vancomycin in Chinese children. Postnatal age and weight significantly influence vancomycin dosing for individualized therapy.

    Area of Science:

    • Pharmacology
    • Pediatric Medicine
    • Clinical Pharmacy

    Background:

    • Vancomycin is crucial for treating serious pediatric infections.
    • Individualized dosing is necessary due to pharmacokinetic variability in children.
    • Developing a population pharmacokinetic (PopPK) model can optimize vancomycin therapy.

    Purpose of the Study:

    • To create a PopPK model for vancomycin in Chinese pediatric patients.
    • To identify key factors influencing vancomycin pharmacokinetics.
    • To support personalized vancomycin treatment strategies.

    Main Methods:

    • Nonlinear mixed-effects modeling (NONMEM) was used.
    • A one-compartment model with first-order elimination was applied.
    • Stepwise covariate modeling identified significant factors; internal validation confirmed model robustness.

    Main Results:

    • The analysis included 54 pediatric patients (128 samples).
    • Postnatal age and body weight were significant covariates affecting vancomycin clearance and volume of distribution.
    • The final PopPK model equations were CL(L/h) = 11.75×[PNA0.4672/(PNA0.4672+33.30.4672)]×(WT/70)0.75×e0.362 and V(L) = 54.49×WT/70×e0.6711.

    Conclusions:

    • A robust PopPK model for vancomycin in Chinese pediatric patients was successfully developed.
    • Identified covariates (postnatal age, weight) enable individualized vancomycin dosing.
    • This model aids in optimizing vancomycin therapy for better clinical outcomes in pediatric patients.
    Abstract

    More Related Videos

    A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically11:28

    A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically

    Published on: September 9, 2015

    29.9K
    A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii09:17

    A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

    Published on: January 2, 2017

    15.3K

    Related Concept Videos

    Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

    Pharmacokinetics in Pediatric Patients: Drug Excretion

    In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
    342
    Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

    Pharmacokinetics in Pediatric Patients: Drug Metabolism

    In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
    304
    Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

    Pharmacokinetics in Pediatric Patients: Drug Distribution

    Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
    405
    Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

    Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

    Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
    575
    Drug Dosing: Infants and Children01:29

    Drug Dosing: Infants and Children

    Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
    615
    Estimation of k and VD of Aminoglycosides01:20

    Estimation of k and VD of Aminoglycosides

    Aminoglycosides are a class of antibiotics used to treat various bacterial infections. Clinicians must determine the elimination rate constant (k) and volume of distribution (VD) to optimize therapeutic efficacy and minimize toxicity. The k value represents the rate at which the drug is removed from the body, and the VD reflects the degree to which the drug distributes into body tissues. Accurately estimating these parameters allows healthcare professionals to tailor drug dosing to individual...
    289